I agree that this site is using cookies. You can find further informations here.
X
Adi Diab
206  results:
Search for persons X
?
1

Survival and treatment outcomes in patients with leptomenin..:

Saberian, Chantal ; Milton, Denái R ; Simon, Julie...
Neuro-Oncology Practice.  11 (2024)  4 - p. 452-463 , 2024
Link: https://doi.org/10.1093/..
 
?
2

Baseline biomarkers of efficacy and on-treatment immune-pro..:

Gogas, Helen ; Ravimohan, Shruthi ; Datta, Antara...
npj Precision Oncology.  8 (2024)  1 - p. , 2024
Link: https://doi.org/10.1038/..
 
?
3

IMUN-05 PHASE II STUDY OF NIVOLUMAB (NIVO) IN COMBINATION W..:

Phillips, Suzanne ; Burton, Elizabeth ; Oliva, Isabella Claudia Glitza...
Neuro-Oncology Advances.  6 (2024)  Supplement_1 - p. i14-i15 , 2024
Link: https://doi.org/10.1093/..
 
?
4

Author Correction: Concurrent intrathecal and intravenous n..:

Glitza Oliva, Isabella C. ; Ferguson, Sherise D. ; Bassett Jr, Roland...
Nature Medicine.  30 (2024)  6 - p. 1787-1787 , 2024
Link: https://doi.org/10.1038/..
 
?
5

Concurrent intrathecal and intravenous nivolumab in leptome..:

Glitza Oliva, Isabella C. ; Ferguson, Sherise D. ; Bassett Jr, Roland...
Nature Medicine.  29 (2023)  4 - p. 898-905 , 2023
Link: https://doi.org/10.1038/..
 
?
6

Safety and effectiveness of combination versus monotherapy ..:

Reid, Pankti ; Sandigursky, Sabina ; Song, Juhee...
OncoImmunology.  12 (2023)  1 - p. , 2023
Link: https://doi.org/10.1080/..
 
?
7

Physician Views on the Provision of Information on Immune C..:

Lopez-Olivo, Maria A. ; Duhon, Gabrielle F. ; Ruiz, Juan I....
Cancers.  15 (2023)  10 - p. 2690 , 2023
Link: https://doi.org/10.3390/..
 
?
8

Infliximab for Treatment of Immune Adverse Events and Its I..:

Parvathareddy, Vishnupriyadevi ; Selamet, Umut ; Sen, Aditi A....
Cancers.  15 (2023)  21 - p. 5181 , 2023
Link: https://doi.org/10.3390/..
 
?
9

Imaging features of immune checkpoint inhibitor-related nep..:

Awiwi, Muhammad O. ; Abudayyeh, Ala ; Abdel-Wahab, Noha...
European Radiology.  33 (2022)  3 - p. 2227-2238 , 2022
Link: https://doi.org/10.1007/..
 
?
10

B Cells Are Required to Generate Optimal Anti-Melanoma Immu..:

Singh, Shubhra ; Roszik, Jason ; Saini, Neeraj...
Frontiers in Immunology.  13 (2022)  - p. , 2022
Link: https://doi.org/10.3389/..
 
?
11

First-in-human study of an OX40 (ivuxolimab) and 4-1BB (uto..:

Hamid, Omid ; Chiappori, Alberto A ; Thompson, John A...
Journal for ImmunoTherapy of Cancer.  10 (2022)  10 - p. e005471 , 2022
Link: https://doi.org/10.1136/..
 
?
12

Neoadjuvant checkpoint inhibitor immunotherapy for resectab..:

Ho, Joel ; Mattei, Jane ; Tetzlaff, Michael...
Frontiers in Oncology.  12 (2022)  - p. , 2022
Link: https://doi.org/10.3389/..
 
?
13

Bempegaldesleukin plus Nivolumab in First-line Metastatic U..:

Siefker-Radtke, Arlene O. ; Cho, Daniel C. ; Diab, Adi...
European Urology.  82 (2022)  4 - p. 365-373 , 2022
Link: https://doi.org/10.1016/..
 
?
14

Utilization of Immunotherapy for the Treatment of Hepatocel..:

Abdelrahim, Maen ; Esmail, Abdullah ; Saharia, Ashish...
Cancers.  14 (2022)  7 - p. 1760 , 2022
Link: https://doi.org/10.3390/..
 
?
15

PIVOT-12: a Phase III Study of Adjuvant Bempegaldesleukin P..:

Eggermont, Alexander MM ; Ascierto, Paolo A ; Khushalani, Nikhil I...
Future Oncology.  18 (2022)  8 - p. 903-913 , 2022
Link: https://doi.org/10.2217/..
 
1-15